Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Basel, 02 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an initial donation of essential medicines to Ukraine. Roche vehemently condemns the violent invasion of the country. Roche...
-
WHO’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countries Since the beginning of the...
-
In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one Almost 80%...
-
Basel, 3 February 2022 Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Division sales increase 3%; continued strong demand for newly launched...
-
Basel, 3. Februar 2022 Konzernverkäufe steigen um 9%1 zu konstanten Wechselkursen (CER); 8% in Schweizer FrankenVerkäufe der Division Pharma steigen um 3%; anhaltend starkes Wachstum der neu...
-
Bâle, le 3 février 2022 Le chiffre d’affaires consolidé augmente de 9%1 à taux de change constants (TCC) et de 8% en francs suissesLe chiffre d’affaires de la division Pharma s’inscrit en hausse de...
-
Basel, 1. Februar 2022Roche (SIX: RO, ROG; OTCQX: RHHBY) hat heute bekannt gegeben, dass William Pao (1967), M.D., Ph.D. und seit 2018 Leiter von Roche Pharma Forschung und Frühe Entwicklung (pRED),...
-
Basel, 1 February 2022 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that William Pao (1967), M.D., Ph.D., and Head of Roche Pharma Research and Early Development (pRED) since 2018, has decided...
-
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only...
-
Interim data submitted to the FDA show majority of pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as...